Stock Analysis·← Pickers

CDXC

ChromaDex Corporation

ChromaDex Corporation (CDXC) is currently in a range/mixed trend, above the 200-day MA but below the 50-day MA. RSI is at 44.3, with 2/3 trend checks passing.

Price
$7.87
-0.07 (-0.88%)
Day range
$7.75–$7.92
52wk $2.31–$9.18
Volume
541.7K
Avg
Trend score
2/3
Range / Mixed
RSI (14)
44.3
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

CDXC with MA50 and MA200

8.557.025.503.972.4404/3007/2610/2101/1604/14
CDXC2024-04-302025-04-14
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$6.50-5.50% vs price
MA200
$4.98+23.34% vs price
RSI (14)
44.3Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

CDXC valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for CDXC

ChromaDex Corporation (CDXC) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $7.87, and 2 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 5.5% and above the 200-day moving average by 23.3%.

Momentum and stretch context

CDXC currently has an RSI reading of 44.3, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

This page is designed to help you quickly understand what the CDXC chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About ChromaDex Corporation

ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Frank Louis Jaksch Jr.
Employees
104
Market cap
$611.9M
Beta
2.21
52-week range
$2.31 – $9.18
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
25 Jun 2008
ISIN
US1710774076
CUSIP
171077407
Company profile data from Financial Modeling Prep. CDXC listed on NASDAQ.
Share dilution

CDXC shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
79.9M
Since Jun 2019
+43.9%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. CDXC28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about CDXC

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.